World Health Organisation (WHO) on Monday approved Bavarian Nordic’s (BAVA.CO) new tab mpox vaccine for adolescents aged 12 to 17 years.
Browsing: Bavarian Nordic
A recent study from Ontario, Canada, has revealed that Bavarian Nordic A/S’s smallpox vaccine, marketed as Imvamune in Canada and Jynneos in the US, was 58% effective in preventing mpox infections after a single dose.
Bavarian Nordic has no plans to sell or manufacture its vaccine directly to African countries, the company’s Vice President of…